Lower Urinary Tract Symptoms: What’s New in Medical Treatment?

    January 2018 in “ European urology focus
    B. Peyronnet, Benjamin Brucker, Martin C. Michel
    Image of study
    TLDR New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
    The document reviewed emerging evidence in the medical treatment of lower urinary tract symptoms (LUTS). Key innovations included the approval of the first β<sub>3</sub>-adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A for overactive bladder (OAB). Promising results were seen in phase 3 trials for other drugs like antiepileptics and phosphodiesterase inhibitors. Combination therapies of phosphodiesterase type 5 inhibitors with α-blockers or finasteride were found superior to single therapies. New formulations of desmopressin were approved for nocturia, and fedovapagon completed a large phase 3 trial for nocturia in males. Ongoing phase 3 trials were investigating treatments for bladder pain syndrome and neurogenic detrusor overactivity. The field of medical treatment for LUTS was very active, with several new and emerging drugs under investigation.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    1 / 1 results